Hangzhou Sciwind Biosciences Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2017-08-17
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sciwind.com.cn
A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT06335134
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
Phase 3
Completed
- Conditions
- Weight Management
- Interventions
- Drug: Ecnoglutide Medium DosageDrug: PlaceboDrug: Ecnoglutide Low DosageDrug: Ecnoglutide High Dosage
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 664
- Registration Number
- NCT05813795
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05779995
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Phase 3
Completed
- Conditions
- Type 2 Diabetes MellitusT2DM
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 623
- Registration Number
- NCT05680129
- Locations
- 🇨🇳
ZHONGSHAN Hospital, Shanghai, Shanghai, China
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 211
- Registration Number
- NCT05680155
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
A Study of XW001 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT05642403
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China